Introduction
Primitive leukemic precursor cells from patients with acute myeloid leukemia (AML) can be identified, characterized and quantitated in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. [1] [2] [3] [4] [5] [6] However, only about 70% of all AML patient samples exhibit detectable engraftment in this mouse model. 2 Various strategies designed in the hope of enhancing AML cell engraftment in NOD/SCID animals, including the injection of cytokines, 2,7-9 cotransplantation of growth factor producing cell lines, or injection of accessory cells, 7, 8 have largely failed to improve on these initial results. In particular, although human growth factor injections into the NOD/SCID mice produce an initial high serum cytokine concentration, it is followed by a rapid decline to undetectable levels within 48 h. 2 In contrast, a number of growth factor producing cell lines are effective in engineering sustained serum levels when transplanted into mice, but have unfortunately proven to be tumorigenic. 8 Most human AML cells, including colony-forming cells (AML-CFC) and long-term culture-initiating cells (AML LTC-IC), are responsive to a variety of growth factors in vitro. [10] [11] [12] Thus, further efforts to supplement the NOD/SCID environment with human cytokines in an attempt to improve the NOD/SL-IC assay seemed warranted. In this report, we test the possibility that NOD/SCID mice transgenic for the human growth factors Steel factor (SF), granulocyte macrophagecolony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) (N/ S-S/GM/3 mice) might provide an improved microenvironment for human AML progenitors. Previous studies using b2 microglobulin-deficient NOD/SCID (N/S-b2m À/À ) mice, which have a reduced innate immunity because of a lack of natural killer cell activity, 13 as recipients for human cord blood transplants have revealed a greater than 11-fold increase in SCID repopulating cell (SRC) frequency than was detected in standard NOD/SCID mice and improved detection of progenitors with myeloid restricted and short-term lympho/myeloid repopulating potential.
14,15 Thus, we also studied the usefulness of N/S-b2m À/À as hosts for AML progenitors. The data demonstrate that, at least for some AML samples, the use of one of these alternative mouse strains increased the frequency of detection and/or the proliferative capacity of NOD/SL-IC.
Study design

Patient samples
Peripheral blood was obtained from 11 patients with newly diagnosed AML after informed consent. AML cells were cryopreserved as previously described. 2 Diagnosis and classification of AML were based on the criteria of the French-AmericanBritish group. 16 Cytogenetic analysis was performed on the bone marrow (BM) at initial diagnosis. For the comparison of NOD/ SCID vs N/S-b2m À/À mice, eight patient samples were selected which were shown to engraft poorly or inconsistently in NOD/ SCID mice, although the cells appeared viable as assessed by trypan blue dye exclusion, 3 H-thymidine incorporation in response to added growth factors, and the formation of blast colonies in AML-CFC assays (data not shown). In addition, to hopefully improve the possibility of observing enhanced engraftment in N/S-S/GM/3 mice, these eight samples were also selected for their growth factor responsiveness in AML-CFC assays and the fact that some evidence of improved engraftment in standard NOD/SCID mice was seen when human IL-3 and human SF were injected 2-3 times a week i.p. into recipient mice following transplantation of AML blasts. 2 One of these eight and the three additional patient samples were analyzed at limiting dilution to determine the frequency of the NOD/SL-IC detected in NOD/ SCID vs N/S-b2m À/À mice (n ¼ 3) or N/S-S/GM/3 (n ¼ 1). For these latter experiments, patient samples were chosen where engraftment in standard NOD/SCID mice was sufficient to allow a control frequency of NOD/SL-IC to be detected. 20 000-100 000 cells/ml in methylcellulose medium supplemented with human growth factors. Cultures were scored after 14 days for the presence of clusters and colonies. 10 In patients with a leukemia-specific clonal chromosomal abnormality colonies were plucked onto 10-well glass slides for fluorescence in situ hybridization (FISH) analysis. LTC were established as previously described 10 by coculturing CD45 + -sorted AML cells at a concentration of 10 3 -10 6 cells/ml in Myelocult LTC media (StemCell Technologies, Vancouver, Canada) with irradiated (80 Gy) Sl/Sl-J-IL3 feeders. 17 After 6 weeks, all cells were harvested and placed into methylcellulose based assay for the detection of AML-CFC as described above.
Mice
NOD/LtSz-scid/scid (NOD/SCID), 18 N/S-b2m À/À mice 13 and congenic NOD/SCID mice genetically engineered to produce elevated serum levels of human IL-3 (1.570.5 ng/ml), human GM-CSF (3.870.5 ng/ml) and human SF (2.070.5 ng/ml) (N/S-S/GM/3 mice), 19 . Femoral BM aspirations were performed on recipient mice every 4 weeks. 20 At 8-12 weeks postinjection, the mice were killed and BM was obtained from the four long bones.
Analysis of mice
Cells for FACS analysis were prepared as described. 2, 6, 20 Briefly, 10 5 cells were incubated for 30 min on ice with either a mouse IgG1 isotype control (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) to evaluate nonspecific immunofluorescence or anti-CD45 FITC (prepared in our centre from American Type Culture Collection [ATCC] clone # HB10508, Rockville, MD, USA) to detect human cells. Cells were washed with HFN and counterstained with 1 mg/ml propidium iodide (PI; Sigma Chemical Co., St Louis, MO, USA). FACS analysis was performed on a FACScan or FACSort flow cytometer (Becton Dickinson). Positive cells were defined as those exhibiting a level of fluorescence that exceeded 99.98% of that obtained with isotype-matched control antibodies. In previous studies, the limit of sensitivity of this analysis technique for detection of human cells is 0.1-0.3%. 2 For the comparison of levels of engraftment shown in Table 1 , the mean %CD45 + cells in mouse BM at a given time point for all mice in a cohort was calculated. For limiting dilution analysis shown in Table 2 , the frequencies of injected NOD/SL-IC were calculated using the Poisson statistics and the method of maximum likelihood using the L-calc software (StemCell). The total number of cells per mouse was calculated by multiplying the number of cells harvested with the %CD45 + divided by 0.25 under the assumption that these four long bones comprise 25% of the total marrow. 21 The number of blasts, CFC and LTC-IC produced per NOD/SL-IC were calculated by dividing the total number of human cells, CFC and LTC-IC by the NOD/SL-IC frequency. 2 
FISH
Cytospins were obtained from the AML samples after FACS sorting. FISH analysis for the detection of the inv16 and +13 abnormality was performed using a yeast artificial chromosome (YAC) clone encompassing the breakpoint on 16p13 (CEPHy904E02854; Max Planck Institut, Berlin, Germany), and the Quint-Essential TM 13-specific DNA probe labeled with DIG (Oncor, Gaithersburg, MD, USA) as described. 2 Slides were analyzed on a Zeiss (Oberkochen, Germany) Axioplan fluorescence microscope. 6 Each colony was only scored if a minimum of five cells showed a clear signal and if at least 80% of the cells showed either the normal or abnormal signal. 10 
Statistical analysis
Comparison of engraftment levels or progenitor frequency between standard NOD/SCID and the two test mouse strains was done using the Student's t-test.
Results and discussion
Higher levels of leukemic engraftment in N/S-b2m
and N/S-S/GM/3 mice vs NOD/SCID mice Table 1 shows the comparison of levels of engraftment for eight AML samples injected into standard NOD/SCID, N/S-b2m À/À , + cells at weeks 8 and 12, respectively, 9.8 and 1.5% for AML sample 3, 4.6, and 0.4% for sample 4, and 1.8 and 3.5% for sample 5. When these same eight samples were tested in N/S-S/GM/3 mice three different samples showed improved engraftment at 8 and/or 12 weeks post-transplant, which had not shown any improvement when transplanted into N/S-b2m À/À mice. The mean %CD45
+ cells in mouse BM at 8 and 12 weeks, respectively, post-transplant into N/S-S/GM/3 mice was 0.16 and 10.7% for sample 1, 12.6 and 0.38% for sample 6, and 23.4 and 74.3% for sample 8 (Po0.05). Two AML samples failed to show improved engraftment in either of the new mouse strains tested. One of these (sample 7) was from a patient with AML-M3 and t(15;17), a leukemic subtype which we have found very difficult to grow in any of our in vitro or in vivo assays for AML progenitors, 2,10 while the second sample (#2) was from a patient with AML-M4 and a normal karyotype.
Improved detection and increased cell production from NOD/SL-IC in N/S-b2m À/À and N/S-S/GM/3 mice as compared to standard NOD/SCID mice To determine if the frequency of NOD/SL-IC detected or the number of cell progeny produced per NOD/SL-IC was altered when AML samples were assayed in the N/S-b2m À/À or N/S-S/ GM/3 mice, limiting dilution analysis was performed with four patient samples as described in the Methods. As shown in Table 2 , the NOD/SL-IC frequency detected was increased sixfold (Po0.05) in sample 9 in the N/S-b2m À/À animals and seven-fold (Po0.05) in sample 6 in the N/S-S/GM/3 mice, while no change in the number of these progenitors was seen with the other two samples tested in the N/S-b2m À/À strain. The results obtained here with sample 9 are consistent with the higher seeding efficiency of cord blood SRC, which others have previously observed in N/S-b2m À/À mice. 13, 15 Interestingly, in contrast with our results with sample 6, similar experiments testing the engraftment capacity of normal human BM cells in N/S-S/GM/3 mice have revealed no significant increase the detection of progenitors with multilineage potential in mouse BM as compared to standard NOD/SCID animals. 19 Using the frequency of NOD/SL-IC calculated from the limiting dilution analysis and the total numbers of leukemic blasts, AML-CFC and AML LTC-IC calculated to be present in mouse BM at the time of this analysis, we determined the numbers of different cell progeny produced per NOD/SL-IC. As shown in Table 2 , there was no consistent difference in the calculated number of blasts produced per NOD/SL-IC between NOD/SCID and N/S-b2m À/À mice, while for the one sample where the comparison between N/S-S/GM/3 and NOD/SCID mice was made there was an apparent five-fold increase in the production of these cells. In two cases, it was possible to confirm the malignant nature of the engrafting cells by the detection of the expected cytogenetic abnormality by FISH. Interestingly, the number of AML-CFC produced per NOD/SL-IC was significantly (P ¼ 0.02) higher in N/S-b2m À/À mice in two of the three patient samples tested (#10 and 11). Similarly, there was a three-fold increase in the number AML LTC-IC produced per NOD/SL-IC from sample 11 in N/S-b2m À/À mice. The BM from this AML patient had revealed a trisomy of chromosome 13 in 38% of the cells at diagnosis. Although this chromosomal change could not be detected in the small number of colonies available for analysis from AML-CFC assays from either mouse strain it was present in eight of the 10 AML LTC-IC-derived colonies analyzed from N/S-b2m À/À BM. This latter finding clearly established the malignant nature of the progenitors recovered from N/S-b2m À/À animals. However, it is likely that at least some of the apparently cytogenetically normal colonies detected were also of leukemic origin. We suspect this to be the case because of the results from other experiments using Xchromosome inactivation-based clonality assays in which we have demonstrated that cytogenetically normal AML-CFC and LTC-IC from this patient sample are nevertheless clonal in origin. 22 In summary, our data demonstrate that N/S-b2m À/À as well as N/S-S/GM/3 mice are suitable for the detection of NOD/ SL-IC. In addition, both strains allow the engraftment and detection of some AML progenitors, which are not detectable in Table 2 Progenitor frequency and cell production per NOD/SL-IC AML engraftment in NOD/SCID mouse strains M Feuring-Buske et al the NOD/SCID mouse model. Both the N/S-b2m À/À and the N/S-S/GM/3 mouse strains appear to provide improved xenograft models for the study of human AML stem cell biology and for more efficient preclinical evaluation of innovative therapeutic strategies. [2] [3] [4] [5] 20, 23 Furthermore, knowledge of the factors which permit better engraftment of certain AML samples in one or the other of these mouse strains may be important to our understanding of the pathophysiology of these leukemias. Experiments are in progress to determine if mice which combine the characteristics of both the N/S-b2m À/À and the N/S-S/GM/3 strain may allow even more AML patient samples to be studied in vivo.
